BRAF inhibitors do not induce phosphorylation of PDH in resistant melanoma cells. Western blot analysis of untreated A375, A375 cells resistant to Vemurafenib (A375-R) and under constant presence of 1 μM of PLX4032 and A375 cells stimulated with 1 μM of PLX4032 for 24 h. α-Tubulin was used as loading control; representative blots of three biological replicates are shown. (PDF 102 kb
Figure S4. Western blot analysis for selected drug treatments and apoptosis assays in healthy and me...
Table S1. Kinase inhibitor library screening. A commercial kinase inhibitor library of 274 compounds...
Figure S3. BRAF inhibitors in combination with selected kinase inhibitors synergistically inhibit pr...
The effect of BRAF inhibitors vemurafenib and PLX8394 on BRAF wt / KRAS G13D cell line HCT 116. Cell...
The effect of vemurafenib and PLX8394 on the BRAF V600E melanoma cell line LM-MEL-64 and the BRAF wt...
Figure S1. Melatonin enhanced the inhibition of cell proliferation by vemurafenib. (A). BRAF V600E, ...
Figure S2. Analysis of cell cycle after treatment with selumetinib or sorafenib and combination. Cel...
Figure 6. Dose-response curves of selected kinase inhibitors in the presence or absence of BRAF inhi...
Figure S1. Dose-response curves of selected kinase inhibitors in parental and BRAFi-resistant A375 c...
Figure S8. Protein phosphorylation screening following β-sitosterol treatment. Parallel determinatio...
Figure S2. Dose-response curves of selected kinase inhibitors in parental and BRAFi-resistant IGR37 ...
Figure S3. Cell viability in vitro by increasing β-sitosterol concentrations. Human melanoma cell li...
RHEB Y35N Exhibits Decreased Binding to BRAF. Cell lysates were collected from NIH 3T3 cell lines st...
peer reviewedBackground: Most melanoma patients with BRAFV600E positive tumors respond well to a com...
A375 growth data. Single-treatment of 10 μM PPL-008C and PPL-008CSS significantly attenuated A375 ce...
Figure S4. Western blot analysis for selected drug treatments and apoptosis assays in healthy and me...
Table S1. Kinase inhibitor library screening. A commercial kinase inhibitor library of 274 compounds...
Figure S3. BRAF inhibitors in combination with selected kinase inhibitors synergistically inhibit pr...
The effect of BRAF inhibitors vemurafenib and PLX8394 on BRAF wt / KRAS G13D cell line HCT 116. Cell...
The effect of vemurafenib and PLX8394 on the BRAF V600E melanoma cell line LM-MEL-64 and the BRAF wt...
Figure S1. Melatonin enhanced the inhibition of cell proliferation by vemurafenib. (A). BRAF V600E, ...
Figure S2. Analysis of cell cycle after treatment with selumetinib or sorafenib and combination. Cel...
Figure 6. Dose-response curves of selected kinase inhibitors in the presence or absence of BRAF inhi...
Figure S1. Dose-response curves of selected kinase inhibitors in parental and BRAFi-resistant A375 c...
Figure S8. Protein phosphorylation screening following β-sitosterol treatment. Parallel determinatio...
Figure S2. Dose-response curves of selected kinase inhibitors in parental and BRAFi-resistant IGR37 ...
Figure S3. Cell viability in vitro by increasing β-sitosterol concentrations. Human melanoma cell li...
RHEB Y35N Exhibits Decreased Binding to BRAF. Cell lysates were collected from NIH 3T3 cell lines st...
peer reviewedBackground: Most melanoma patients with BRAFV600E positive tumors respond well to a com...
A375 growth data. Single-treatment of 10 μM PPL-008C and PPL-008CSS significantly attenuated A375 ce...
Figure S4. Western blot analysis for selected drug treatments and apoptosis assays in healthy and me...
Table S1. Kinase inhibitor library screening. A commercial kinase inhibitor library of 274 compounds...
Figure S3. BRAF inhibitors in combination with selected kinase inhibitors synergistically inhibit pr...